Загрузка...
Daclizumab reverses intrathecal immune cell abnormalities in multiple sclerosis
OBJECTIVE: Novel treatments such as natalizumab and fingolimod achieve their therapeutic efficacy in multiple sclerosis (MS) by blocking access of subsets of immune cells into the central nervous system, thus creating nonphysiological intrathecal immunity. In contrast, daclizumab, a humanized monocl...
Сохранить в:
| Опубликовано в: : | Ann Clin Transl Neurol |
|---|---|
| Главные авторы: | , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
BlackWell Publishing Ltd
2015
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4435700/ https://ncbi.nlm.nih.gov/pubmed/26000318 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/acn3.181 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|